6. Medications adherence in patients with osteoporosis after vertebroplasty or kyphoplasty at Hanoi Medical University Hospital
Nội dung chính của bài viết
Tóm tắt
Poor adherence to medication therapy is currently one of the most critical obstacles facing osteoporosis care and it is one of the main barriers for optimal therapeutic osteoporosis management, especially after surgical intervention. This paper presents medication adherence and explores factors associated with medications non-adherence in patients with osteoporosis after vertebroplasty or kyphoplasty. This is a retrospective case series included osteoporosis patients underwent vertebroplasty or kyphoplasty at Hanoi Medical University Hospital in 2019. Medication adherence was assessed using the validated Osteoporosis specific Morisky Medication Adherence Scale. A total of 42 patients participated in the study. Level of osteoporosis medication adherence decreased gradually with time of using medication: high adherence level after 1 month with OS-MMAS score was 8. Mean score of medium and low adherence after 3 months and 6 months were 6.64 ± 1.19 and 4.64 ± 2.18, respectively . 57.14% of participants had low adherence (6 months). 73.81% patients forgot to take medication. The associated factors of medication adherence are residence area, occupation, education level, number of medication used, frequency of osteoporosis medication, failure to take medication and side effects. The current study reveals a low level of medication adherence and sheds the light on different causes of medication non-adherence among patients with osteoporosis after vertebroplasty or kyphoplasty. Identifying barriers for medication non-adherence is an important initial step for developing effective clinical pharmacy interventions for patients with osteoporosis.
Chi tiết bài viết
Từ khóa
Medication adherence, osteoporosis, vertebroplasty, kyphoplasty.
Tài liệu tham khảo
2. Halpern R, Becker L, Iqbal SU, Kazis LE, Macarios D, Badamgarav E. The association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosis. J Manag Care Pharm. 2011; 17(1): 25-39. doi:10.18553/jmcp.2011.17.1.25.
3. Ho-Pham LT, Mai LD, Pham HN, Nguyen ND, Nguyen TV. Reference ranges for vertebral heights and prevalence of asymptomatic (undiagnosed) vertebral fracture in Vietnamese men and women. Arch Osteoporos. 2012; 7: 257-266. doi:10.1007/s11657-012-0106-z.
4. Zhang H, Xu C, Zhang T, Gao Z, Zhang T. Does Percutaneous Vertebroplasty or Balloon Kyphoplasty for Osteoporotic Vertebral Compression Fractures Increase the Incidence of New Vertebral Fractures? A Meta-Analysis. Pain Physician. 2017; 20(1): E13-E28.
5. Nishimura A, Akeda K, Kato K, et al. Osteoporosis, vertebral fractures and mortality in a Japanese rural community. Modern Rheumatology. 2014; 24(5): 840-843. doi:10.3109/14397595.2013.866921.
6. Galibert P, Deramond H, Rosat P, Le Gars D. Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty. Neurochirurgie. 1987; 33(2): 166-168.
7. Abebaw M, Messele A, Hailu M, Zewdu F. Adherence and Associated Factors towards Antidiabetic Medication among Type II Diabetic Patients on Follow-Up at University of Gondar Hospital, Northwest Ethiopia. In:; 2016. doi:10.1155/2016/8579157.
8. Kleinsinger F. The Unmet Challenge of Medication Nonadherence. Perm J. 2018; 22: 18-033. doi:10.7812/TPP/18-033.
9. Jarab A, Mukattash T, Hilan H. Medication non-adherence in patients with osteoporosis: implications for clinical pharmacists and osteoporosis care providers. Curr Clin Pharmacol. Published online January 15, 2020. doi:10.2174/1574884715666200116104754.
10. Hall SF, Edmonds SW, Lou Y, et al. Patient-reported reasons for nonadherence to recommended osteoporosis pharmacotherapy. Journal of the American Pharmacists Association. 2017; 57(4): 503-509. doi:10.1016/j.japh.2017.05.003.
11. Hadji P, Felsenberg D, Amling M, Hofbauer LC, Kandenwein JA, Kurth A. The non-interventional BonViva Intravenous Versus Alendronate (VIVA) study: real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis. Osteoporos Int. 2014; 25(1):339-347. doi:10.1007/s00198-013-2515-2.
12. Reynolds K, Viswanathan HN, O’Malley CD, et al. Psychometric Properties of the Osteoporosis-Specific Morisky Medication Adherence Scale in Postmenopausal Women with Osteoporosis Newly Treated with Bisphosphonates. Ann Pharmacother. 2012; 46(5): 659-670. doi:10.1345/aph.1Q652.
13. Hadji P, Papaioannou N, Gielen E, et al. Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study. Osteoporos Int. 2015; 26(10): 2479-2489. doi:10.1007/s00198-015-3164-4.
14. Horne R, Chapman SCE, Parham R, Freemantle N, Forbes A, Cooper V. Understanding patients’ adherence-related beliefs about medicines prescribed for long-term conditions: a meta-analytic review of the Necessity-Concerns Framework. PLoS One. 2013; 8(12): e80633. doi:10.1371/journal.pone.0080633.
15. Yood RA, Mazor KM, Andrade SE, Emani S, Chan W, Kahler KH. Patient decision to initiate therapy for osteoporosis: the influence of knowledge and beliefs. J Gen Intern Med. 2008; 23(11): 1815-1821. doi:10.1007/s11606-008-0772-0.
16. Tran Thi My Hanh (2018). Evaluation of intervention outcomes to improve practice of selfmonitoring of blood pressure and adherence to treatment. College of Public Health.